title: [Results of phase II clinical trial of vindesine in the treatment of malignant tumors].
abstract: A phase III clinical trial of vindesine-containing regimens organized by Chinese Medical Association was conducted from November 1993 to October 1994. In 799 evaluable cases, the overall response rate was 64.5% and the individual response rate was 74.1% for SCLC, 52.6% for NSCLC, 88.0% for malignant lymphomas, 62.6% for breast cancer, 57.5% for esophageal carcinoma, 59.0% for overian carcinoma and 94.0% for ALL. There were 1532 patients evaluable for toxicity. The dose-limiting toxicity was myelosuppression. Gastro-intestinal reactions, peripheral neuritis, alopecia and phlebtitis were also common. It is concluded that vindesine is similar to that reported as to response rate and toxicity.
authors.affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: Y
authors.initials: Y
authors.lastname: Sun
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002681:China; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014751:Vindesine / Q000008:administration & dosage*
chemical_list: D014751:Vindesine